Fran Aweeka, PharmD
Professor
Clinical Pharmacy
School of Pharmacy

The Drug Research Unit (DRU, also known as the Global Health Pharmacology Laboratory) for which Dr. Aweeka serves as Director, is recognized for state of the art analytical techniques for quantification of HIV, malaria, TB and oncology drugs in plasma, dried blood spots or within target cells or tissues and these methods are used to support numerous research investigations. Dr. Aweeka serves as PI on an NIH RO1 on PK/PD of malaria and antiretroviral drugs in HIV co-infected children and women in Uganda. The DRU serves as a Pharmacology Core for DAIDS programs; e.g. AIDS Clinical Trials Group and the Center for AIDS Research (supporting >30 NIH studies). Dr. Aweeka has completed the Mentor Development Program and is willing to mentor faculty, fellows, residents and students interested in an academic research career.

• The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Wang K, Li F, Mwebaza N, Aweeka FT, Parikh S
• Evaluating the effect of atorvastatin exposure and vitamin D levels on lipid outcomes in people with HIV-1 with suppressed HIV-1 RNA and LDL cholesterol <130 mg/dL.
  HIV medicine 2022 Rahman F, Brates I, Aweeka F, Bosch RJ, Deitchman A, Nixon D, Aberg JA
• Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
  Clinical pharmacology and therapeutics 2022 Kay K, Goodwin J, Ehrlich H, Ou J, Freeman T, Wang K, Li F, Wade M, French J, Huang L, Aweeka F, Mwebaza N, Kajubi R, Riggs M, Ruiz-Garcia A, Parikh S
• Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Hughes E, Wallender E, Kajubi R, Jagannathan P, Ochieng T, Kakuru A, Kamya MR, Clark TD, Rosenthal PJ, Dorsey G, Aweeka F, Savic RM
• Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies.
  Journal of chromatography open 2022 Huang L, Winger BA, Cheah V, Gingrich D, Marzan F, Lu Y, Cooper JC, Aweeka F, Long-Boyle J
• Determination of unbound piperaquine in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry.
  Journal of chromatography open 2022 Huang L, Sok V, Aslam-Mir U, Marzan F, Whalen M, Rosenthal PJ, Aweeka F
• Differential toxicity to murine small and large intestinal epithelium induced by oncology drugs.
  Communications biology 2022 Bieber JM, Sanman LE, Sun X, Hammerlindl H, Bao F, Roth MA, Koleske ML, Huang L, Aweeka F, Wu LF, Altschuler SJ
• Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children.
  Nature communications 2021 Wallender E, Ali AM, Hughes E, Kakuru A, Jagannathan P, Muhindo MK, Opira B, Whalen M, Huang L, Duvalsaint M, Legac J, Kamya MR, Dorsey G, Aweeka F, Rosenthal PJ, Savic RM
• Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms.
  Cell reports 2021 Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, Donatelli J, Thanh C, Takahashi S, Hakim J, Turcios K, Janson O, Hoh R, Tai V, Hernandez Y, Fehrman EA, Spinelli MA, Gandhi M, Trinh L,…
• Abnormal Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human Immunodeficiency Virus.
  The Journal of infectious diseases 2021 Schnittman SR, Deitchman AN, Beck-Engeser G, Ahn H, York VA, Hartig H, Hecht FM, Martin JN, Deeks SG, Aweeka FT, Hunt PW
• Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092.
  The Pediatric infectious disease journal 2021 Owor M, Tierney C, Ziemba L, Browning R, Moye J, Graham B, Reding C, Costello D, Norman J, Wiesner L, Hughes E, Whalen ME, Purdue L, Mmbaga BT, Kamthunzi P, Kawalazira R, Nathoo K, Bradford S, Coletti…
• Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma.
  PloS one 2021 Sok V, Marzan F, Gingrich D, Aweeka F, Huang L
• Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19.
  medRxiv : the preprint server for health sciences 2021 Peluso MJ, Deitchman AN, Torres L, Iyer NS, Nixon CC, Munter SE, Donatelli J, Thanh C, Takahashi S, Hakim J, Turcios K, Janson O, Hoh R, Tai V, Hernandez Y, Fehrman E, Spinelli MA, Gandhi M, Trinh L, …
• Exposure to pesticides in utero impacts the fetal immune system and response to vaccination in infancy.
  Nature communications 2021 Prahl M, Odorizzi P, Gingrich D, Muhindo M, McIntyre T, Budker R, Jagannathan P, Farrington L, Nalubega M, Nankya F, Sikyomu E, Musinguzi K, Naluwu K, Auma A, Kakuru A, Kamya MR, Dorsey G, Aweeka F, …
• Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV.
  Journal of acquired immune deficiency syndromes (1999) 2020 Gingrich D, Deitchman AN, Kantor A, Huang L, Stein JH, Currier JS, Hsue PY, Ribaudo HJ, Aweeka FT, ACTG 5314 Protocol Team
• Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women.
  Antimicrobial agents and chemotherapy 2020 Hughes E, Imperial M, Wallender E, Kajubi R, Huang L, Jagannathan P, Zhang N, Kakuru A, Natureeba P, Mwima MW, Muhindo M, Mwebaza N, Clark TD, Opira B, Nakalembe M, Havlir D, Kamya M, Rosenthal PJ, …
• Therapeutic Efficacy of Artemether-Lumefantrine for Uncomplicated Falciparum Malaria in Northern Zambia.
  The American journal of tropical medicine and hygiene 2020 Ippolito MM, Pringle JC, Siame M, Katowa B, Aydemir O, Oluoch PO, Huang L, Aweeka FT, Bailey JA, Juliano JJ, Meshnick SR, Shapiro TA, Moss WJ, Thuma PE
• Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2020 Henrich TJ, Schreiner C, Cameron C, Hogan LE, Richardson B, Rutishauser RL, Deitchman AN, Chu S, Rogers R, Thanh C, Gibson EA, Zarinsefat A, Bakkour S, Aweeka F, Busch MP, Liegler T, Baker C, Milush J…
• Determination of piperaquine concentration in human plasma and the correlation of capillary versus venous plasma concentrations.
  PloS one 2020 Mwebaza N, Cheah V, Forsman C, Kajubi R, Marzan F, Wallender E, Dorsey G, Rosenthal PJ, Aweeka F, Huang L
• Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
  Clinical pharmacology and therapeutics 2020 Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F, Luetkemeyer AF, Savic RM
• An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.
  Antimicrobial agents and chemotherapy 2020 Francis J, Barnes KI, Workman L, Kredo T, Vestergaard LS, Hoglund RM, Byakika-Kibwika P, Lamorde M, Walimbwa SI, Chijioke-Nwauche I, Sutherland CJ, Merry C, Scarsi KK, Nyagonde N, Lemnge MM, Khoo SH, …
• Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.
  Pharmacogenetics and genomics 2020 Haas DW, Cramer YS, Godfrey C, Rosenkranz SL, Aweeka F, Berzins B, Coombs R, Coughlin K, Moran LE, Gingrich D, Zorrilla CD, Baker P, Cohn SE, Scarsi KK, AIDS Clinical Trials Group A5316 Study Team
• Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
  Journal of acquired immune deficiency syndromes (1999) 2020 Hughes E, Mwebaza N, Huang L, Kajubi R, Nguyen V, Nyunt MM, Orukan F, Mwima MW, Parikh S, Aweeka F
• Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
  The lancet. HIV 2019 Scarsi KK, Cramer YS, Rosenkranz SL, Aweeka F, Berzins B, Coombs RW, Coughlin K, Moran LE, Zorrilla CD, Akelo V, Aziz M, Friedman RK, Gingrich D, Swaminathan S, Godfrey C, Cohn SE, AIDS Clinical …
• Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.
  Clinical pharmacology and therapeutics 2019 Whalen ME, Kajubi R, Chamankhah N, Huang L, Orukan F, Wallender E, Kamya MR, Dorsey G, Jagannathan P, Rosenthal PJ, Mwebaza N, Aweeka FT
• Comparison on simultaneous caillary and venous parasite density and genotyping results from children and adults with uncomplicated malaria: a prospective observational study in Uganda.
  BMC infectious diseases 2019 Lehane A, Were M, Wade M, Hamadu M, Cahill M, Kiconco S, Kajubi R, Aweeka F, Mwebaza N, Li F, Parikh S
• High Kynurenine:Tryptophan Ratio Is Associated With Liver Fibrosis in HIV-Monoinfected and HIV/Hepatitis C Virus-Coinfected Women.
  Open forum infectious diseases 2019 Kardashian A, Ma Y, Yin MT, Scherzer R, Nolan O, Aweeka F, Tien PC, Price JC
• Determination of melphalan in human plasma by UPLC-UV method.
  Cancer chemotherapy and pharmacology 2019 Huang L, Cheah V, Chan D, Marzan F, Dvorak CC, Aweeka FT, Long-Boyle J
• Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.
  Antimicrobial agents and chemotherapy 2019 Wallender E, Zhang N, Conrad M, Kakuru A, Muhindo M, Tumwebaze P, Kajubi R, Mota D, Legac J, Jagannathan P, Havlir D, Kamya M, Dorsey G, Aweeka F, Rosenthal PJ, Savic RM
• Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing.
  Antimicrobial agents and chemotherapy 2018 Ali AM, Penny MA, Smith TA, Workman L, Sasi P, Adjei GO, Aweeka F, Kiechel JR, Jullien V, Rijken MJ, McGready R, Mwesigwa J, Kristensen K, Stepniewska K, Tarning J, Barnes KI, Denti P, WWARN …
• Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018 Savic RM, Jagannathan P, Kajubi R, Huang L, Zhang N, Were M, Kakuru A, Muhindo MK, Mwebaza N, Wallender E, Clark TD, Opira B, Kamya M, Havlir DV, Rosenthal PJ, Dorsey G, Aweeka FT
• Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients.
  PloS one 2018 Huang L, Mwebaza N, Kajubi R, Marzan F, Forsman C, Parikh S, Aweeka FT
• Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial.
  PLoS medicine 2018 Jagannathan P, Kakuru A, Okiring J, Muhindo MK, Natureeba P, Nakalembe M, Opira B, Olwoch P, Nankya F, Ssewanyana I, Tetteh K, Drakeley C, Beeson J, Reiling L, Clark TD, Rodriguez-Barraquer I, …
• Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
  PLoS medicine 2018 Kloprogge F, Workman L, Borrmann S, Tékété M, Lefèvre G, Hamed K, Piola P, Ursing J, Kofoed PE, Mårtensson A, Ngasala B, Björkman A, Ashton M, Friberg Hietala S, Aweeka F, Parikh S, Mwai L, Davis TME,…
• Elevated plasma abscisic acid is associated with asymptomatic falciparum malaria and with IgG-/caspase-1-dependent immunity in Plasmodium yoelii-infected mice.
  Scientific reports 2018 Glennon EKK, Megawati D, Torrevillas BK, Ssewanyana I, Huang L, Aweeka F, Greenhouse B, Adams LG, Luckhart S
• Determination of Tobramycin in M9 Medium by LC-MS/MS: Signal Enhancement by Trichloroacetic Acid.
  Journal of analytical methods in chemistry 2018 Huang L, Haagensen JAJ, Verotta D, Cheah V, Spormann AM, Aweeka F, Yang K
• Semi-quantitative measurement of the antimalarial lumefantrine from untreated dried blood spots using LC-MS/MS.
  Journal of pharmaceutical and biomedical analysis 2018 Ippolito MM, Huang L, Siame M, Thuma P, Shapiro TA, Aweeka FT
• Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz.
  The Journal of infectious diseases 2018 Wallender E, Vucicevic K, Jagannathan P, Huang L, Natureeba P, Kakuru A, Muhindo M, Nakalembe M, Havlir D, Kamya M, Aweeka F, Dorsey G, Rosenthal PJ, Savic RM
• Response to "Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction".
  Clinical pharmacology and therapeutics 2018 Jagannathan P, Kajubi R, Aweeka FT
• Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Uganda.
  The Journal of infectious diseases 2017 Conrad MD, Mota D, Foster M, Tukwasibwe S, Legac J, Tumwebaze P, Whalen M, Kakuru A, Nayebare P, Wallender E, Havlir DV, Jagannathan P, Huang L, Aweeka F, Kamya MR, Dorsey G, Rosenthal PJ
• Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
  PloS one 2017 Huang L, Carey V, Lindsey JC, Marzan F, Gingrich D, Graham B, Barlow-Mosha L, Ssemambo PK, Kamthunzi P, Nachman S, Parikh S, Aweeka FT, IMPAACT P1079 protocol team
• Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2017 Ivaturi V, Dvorak CC, Chan D, Liu T, Cowan MJ, Wahlstrom J, Stricherz M, Jennissen C, Orchard PJ, Tolar J, Pai SY, Huang L, Aweeka F, Long-Boyle J
• Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.
  Clinical pharmacology and therapeutics 2017 Kajubi R, Huang L, Jagannathan P, Chamankhah N, Were M, Ruel T, Koss CA, Kakuru A, Mwebaza N, Kamya M, Havlir D, Dorsey G, Rosenthal PJ, Aweeka FT
• A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy.
  Open forum infectious diseases 2017 O'Brien MP, Hunt PW, Kitch DW, Klingman K, Stein JH, Funderburg NT, Berger JS, Tebas P, Clagett B, Moisi D, Utay NS, Aweeka F, Aberg JA
• Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children.
  Open forum infectious diseases 2016 Kajubi R, Huang L, Were M, Kiconco S, Li F, Marzan F, Gingrich D, Nyunt MM, Ssebuliba J, Mwebaza N, Aweeka FT, Parikh S
• Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.
  The Journal of infectious diseases 2016 Tchaparian E, Sambol NC, Arinaitwe E, McCormack SA, Bigira V, Wanzira H, Muhindo M, Creek DJ, Sukumar N, Blessborn D, Tappero JW, Kakuru A, Bergqvist Y, Aweeka FT, Parikh S
• Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, Li F, Were M, Kakuru A, Achan J, Mwebaza N, Aweeka FT
• Effective Antimalarial Chemoprevention in Childhood Enhances the Quality of CD4+ T Cells and Limits Their Production of Immunoregulatory Interleukin 10.
  The Journal of infectious diseases 2016 Jagannathan P, Bowen K, Nankya F, McIntyre TI, Auma A, Wamala S, Sikyomu E, Naluwu K, Nalubega M, Boyle MJ, Farrington LA, Bigira V, Kapisi J, Aweeka F, Greenhouse B, Kamya M, Dorsey G, Feeney ME
• Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women.
  Journal of acquired immune deficiency syndromes (1999) 2016 Weinberg A, Park JG, Bosch R, Cho A, Livingston E, Aweeka F, Cramer Y, Watts DH, Luque AE, Cohn SE
• Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.
  Journal of acquired immune deficiency syndromes (1999) 2015 Dumond JB, Rigdon J, Mollan K, Tierney C, Kashuba AD, Aweeka F, Collier AC
• Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria.
  Antimicrobial agents and chemotherapy 2015 Nyunt MM, Nguyen VK, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Mwima MW, Achan J, Aweeka F, Parikh S, Mwebaza N
• Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.
  Malaria journal 2015 Sundell K, Jagannathan P, Huang L, Bigira V, Kapisi J, Kakuru MM, Savic R, Kamya MR, Dorsey G, Aweeka F
• Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
  Antimicrobial agents and chemotherapy 2015 Parikh S, Fehintola F, Huang L, Olson A, Adedeji WA, Darin KM, Morse GD, Murphy RL, Taiwo BO, Akinyinka OO, Adewole IF, Aweeka FT, Scarsi KK
• PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150.
  Jacobs journal of AIDS/HIV 2015 Sha BE, Tierney C, Sun X, Stek A, Cohn SE, Coombs RW, Bastow B, Aweeka FT, AIDS Clinical Trials Group (ACTG) 5153s Team
• Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.
  Clinical pharmacology and therapeutics 2015 Sambol NC, Yan L, Creek DJ, McCormack SA, Arinaitwe E, Bigira V, Wanzira H, Kakuru A, Tappero JW, Lindegardh N, Tarning J, Nosten F, Aweeka FT, Parikh S
• Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015 Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, …
• The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.
  The Pediatric infectious disease journal 2015 Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F
• Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study.
  Antimicrobial agents and chemotherapy 2015 Luque AE, Cohn SE, Park JG, Cramer Y, Weinberg A, Livingston E, Klingman KL, Aweeka F, Watts DH
• Raltegravir pharmacokinetics during pregnancy.
  Journal of acquired immune deficiency syndromes (1999) 2014 Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, Mirochnick M, IMPAACT 1026s study team
• Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial.
  AIDS (London, England) 2014 Kamya MR, Kapisi J, Bigira V, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Kakuru A, Aweeka FT, Huang L, Jagannathan P, Achan J, Havlir DV, Rosenthal PJ, Dorsey G
• Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics.
  HIV medicine 2014 Aweeka FT, Hu C, Huang L, Best BM, Stek A, Lizak P, Burchett SK, Read JS, Watts H, Mirochnick M, Capparelli EV, International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1026s …
• Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
  Annals of internal medicine 2014 Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson…
• Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.
  Annals of internal medicine 2014 Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson…
• Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial.
  PLoS medicine 2014 Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Osterbauer B, Aweeka FT, Huang L, Achan J, Havlir DV, Rosenthal PJ, Kamya MR, Dorsey G
• Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.
  Antimicrobial agents and chemotherapy 2014 Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW, AIDS Clinical Trials Group A5306 Study Team
• Determination of meropenem in bacterial media by LC-MS/MS.
  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2014 Huang L, Haagensen J, Verotta D, Lizak P, Aweeka F, Yang K
• Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS.
  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2014 Huang L, Lizak P, Dvorak CC, Aweeka F, Long-Boyle J
• Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy.
  The Journal of antimicrobial chemotherapy 2014 Scarsi KK, Fehintola FA, Ma Q, Aweeka FT, Darin KM, Morse GD, Akinola IT, Adedeji WA, Lindegardh N, Tarning J, Ojengbede O, Adewole IF, Taiwo B, Murphy RL, Akinyinka OO, Parikh S
• Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LC-MS/MS.
  Bioanalysis 2014 Kjellin LL, Dorsey G, Rosenthal PJ, Aweeka F, Huang L
• Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.
  Journal of clinical pharmacology 2013 Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F
• Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS.
  Journal of pharmaceutical and biomedical analysis 2013 Huang L, Lizak P, Aweeka F, Long-Boyle J
• Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding.
  Journal of acquired immune deficiency syndromes (1999) 2013 Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, Huang Y, Clark T, Ades V, Natureeba P, Luwedde FA, Achan J, Kamya MR, Havlir DV, Cohan D, Prevention of Malaria and HIV disease in …
• Interactions between alcohol and the HIV entry inhibitor Maraviroc.
  Journal of the International Association of Providers of AIDS Care 2013 Gruber VA, Rainey PM, Lum PJ, Beatty GW, Aweeka FT, McCance-Katz EF
• Determination of artemether and dihydroartemisinin in human plasma with a new hydrogen peroxide stabilization method.
  Bioanalysis 2013 Huang L, Olson A, Gingrich D, Aweeka FT
• Nevirapine inhibits the anti-HIV activity of CD8+ cells.
  Journal of acquired immune deficiency syndromes (1999) 2013 Liu L, Wang L, Huang L, Siu V, Teque F, Aweeka FT, Levy JA
• Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013 Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F, Adult AIDS Clinical Trials Group A5221 Study Team
• Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir.
  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2013 Gwaza L, Aweeka F, Greenblatt R, Lizak P, Huang L, Guglielmo BJ
• Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.
  Antimicrobial agents and chemotherapy 2013 Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO
• Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.
  The Journal of infectious diseases 2013 Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, Tappero JW, Sandison TG, Lindegardh N, Nosten F, Aweeka FT, Parikh S
• Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012 Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng EH, Kwarisiima D, Wong JK, Abdel-Mohsen M, Sonawane N, Aweeka FT, Thirumurthy H, Petersen ML, Charlebois ED, Kamya MR, Havlir DV, SEARCH …
• Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.
  The New England journal of medicine 2012 Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, Kamya MR
• Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.
  Journal of acquired immune deficiency syndromes (1999) 2012 Huang L, Parikh S, Rosenthal PJ, Lizak P, Marzan F, Dorsey G, Havlir D, Aweeka FT
• Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.
  Antimicrobial agents and chemotherapy 2012 Nikanjam M, Kabamba D, Cressey TR, Burger D, Aweeka FT, Acosta EP, Spector SA, Capparelli EV
• In vitro metabolism of piperaquine is primarily mediated by CYP3A4.
  Xenobiotica; the fate of foreign compounds in biological systems 2012 Lee TM, Huang L, Johnson MK, Lizak P, Kroetz D, Aweeka F, Parikh S
• Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.
  AIDS (London, England) 2012 Dong BJ, Zheng Y, Hughes MD, Frymoyer A, Verotta D, Lizak P, Sawe F, Currier JS, Lockman S, Aweeka FT, AIDS Clinical Trials Group Study 5208 Team
• Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.
  Journal of acquired immune deficiency syndromes (1999) 2012 Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C, ACTG 5267 Study Team
• Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults.
  AIDS research and treatment 2012 Fehintola FA, Scarsi KK, Ma Q, Parikh S, Morse GD, Taiwo B, Akinola IT, Adewole IF, Lindegardh N, Phakderaj A, Ojengbede O, Murphy RL, Akinyinka OO, Aweeka FT
• Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation.
  Bioanalysis 2012 Huang L, Li X, Marzan F, Lizak PS, Aweeka FT
• Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150.
  HIV clinical trials 2011 Sha BE, Tierney C, Cohn SE, Sun X, Coombs RW, Frenkel LM, Kalams SA, Aweeka FT, Bastow B, Bardeguez A, Kmack A, Stek A, Aids Clinical Trials Group ACTG A5150 Team
• Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.
  Journal of acquired immune deficiency syndromes (1999) 2010 Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, Klingman KL, Cohn SE
• Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.
  Journal of acquired immune deficiency syndromes (1999) 2010 Taylor SA, Lee GA, Pao VY, Anthonypillai J, Aweeka FT, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C
• CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.
  Journal of acquired immune deficiency syndromes (1999) 2010 Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA
• Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease.
  Science translational medicine 2010 Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, Barbour JD, Lowe MM, Jayawardene A, Aweeka F, Huang Y, Douek DC, Brenchley JM, Martin JN, Hecht FM, Deeks SG, McCune JM
• A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study.
  Analytical chemistry insights 2010 Huang L, Lizak PS, Jayewardene AL, Marzan F, Lee MN, Aweeka FT
• The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers.
  AIDS (London, England) 2010 Pao VY, Lee GA, Taylor S, Aweeka FT, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C
• Lopinavir protein binding in HIV-1-infected pregnant women.
  HIV medicine 2009 Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, Burchett SK, Read J, Mirochnick M, Capparelli EV, International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1026s …
• Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
  Antimicrobial agents and chemotherapy 2009 Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, Clark TD, Dorsey G, Lindegardh N, Annerberg A, Rosenthal PJ, Kamya MR, Aweeka F
• Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.
  PloS one 2009 Yilmaz A, Gisslén M, Spudich S, Lee E, Jayewardene A, Aweeka F, Price RW
• Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
  Journal of acquired immune deficiency syndromes (1999) 2009 German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, Charlebois E, Hanpithakpong W, Lindegardh N, Aweeka FT
• Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma.
  Journal of pharmaceutical and biomedical analysis 2009 Huang L, Jayewardene AL, Li X, Marzan F, Lizak PS, Aweeka FT
• Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy.
  Antimicrobial agents and chemotherapy 2009 Eron JJ, Park JG, Haubrich R, Aweeka F, Bastow B, Pakes GE, Yu S, Wu H, Richman DD, ACTG5126 Study Team
• Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma.
  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008 Huang L, Marzan F, Jayewardene AL, Lizak PS, Li X, Aweeka FT
• Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008 Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, Margolis DM, Patel SS, Barnas D, Frenkel L, Coombs RW, Aweeka F, Morse GD, Haas DW, Boltz V, Palmer S, Coffin J, Havlir DV
• Pharmacokinetics of zidovudine and lamivudine during oral uridine supplementation with NucleomaxX.
  Journal of acquired immune deficiency syndromes (1999) 2008 Venhoff N, Venhoff AC, Jayewardene AL, Aweeka F, Lebrecht D, Walker UA
• Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
  HIV medicine 2008 Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, Best B, Smith E, Read JS, Watts H, Nachman S, Thorpe EM, Spector SA, Jimenez E, Shearer WT, Foca M, Mirochnick M, PACTG 1026S Study Team, …
• Clinical pharmacology of artemisinin-based combination therapies.
  Clinical pharmacokinetics 2008 German PI, Aweeka FT
• CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
  AIDS (London, England) 2007 Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA
• Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.
  AIDS (London, England) 2007 Lee GA, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, Schambelan M, Grunfeld C
• Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team.
  HIV medicine 2007 Aweeka FT, Kang M, Yu JY, Lizak P, Alston B, Chung RT, AIDS Clinical Trials Group 5092s Study Team
• Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007 German P, Greenhouse B, Coates C, Dorsey G, Rosenthal PJ, Charlebois E, Lindegardh N, Havlir D, Aweeka FT
• The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine.
  AIDS (London, England) 2006 Aweeka FT, Rosenkranz SL, Segal Y, Coombs RW, Bardeguez A, Thevanayagam L, Lizak P, Aberg J, Watts DH, NIAID AIDS Clinical Trials Group
• Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006 Lee GA, Lo JC, Aweeka F, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C
• HIV pharmacology: barriers to the eradication of HIV from the CNS.
  HIV clinical trials 2006 McGee B, Smith N, Aweeka F
• Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions.
  HIV medicine 2006 Motoya T, Thevanayagam LN, Blaschke TF, Au S, Stone JA, Jayewardene AL, Chi J, Aweeka FT
• Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.
  The Journal of infectious diseases 2005 Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN
• Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS.
  HIV clinical trials 2005 Jacobson MA, Nicolau DP, Sutherland C, Smith A, Aweeka F
• A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis.
  Antiviral research 2004 Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweeka F, Nadler PI, Sattler F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo A, Pollard RB, AACTG 266 Team
• The metabolic effects of lopinavir/ritonavir in HIV-negative men.
  AIDS (London, England) 2004 Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M, Grunfeld C
• Sex differences in pharmacokinetics and pharmacodynamics.
  Annual review of pharmacology and toxicology 2004 Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF
• Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships.
  Clinical pharmacology and therapeutics 2003 Soy D, Aweeka FT, Church JA, Cunningham CK, Palumbo P, Kosel BW, Sheiner LB, Pediatric AIDS Clinical Trial Group (PACTG) Study P1005 Investigators
• Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377.
  Pediatrics 2003 Floren LC, Wiznia A, Hayashi S, Jayewardene A, Stanley K, Johnson G, Nachman S, Krogstad P, Aweeka FT, Pediatric AIDS Clinical Trials Group 377 Protocol Team
• Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial.
  Annals of internal medicine 2003 Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M
• Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women.
  AIDS (London, England) 2003 Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT
• An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma.
  Journal of pharmaceutical and biomedical analysis 2003 Chi J, Jayewardene AL, Stone JA, Aweeka FT
• Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267.
  The Journal of infectious diseases 2002 Wohl DA, Aweeka FT, Schmitz J, Pomerantz R, Cherng DW, Spritzler J, Fox L, Simpson D, Bell D, Holohan MK, Thomas S, Robinson W, Kaplan G, Teppler H, National Institute of Allergy and Infectious …
• Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.
  AIDS (London, England) 2002 Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C
• Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.
  AIDS (London, England) 2002 Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F, NIAID AIDS Clinical Trials Group
• The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir.
  AIDS (London, England) 2002 Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, Abrams DI
• A direct determination of thymidine triphosphate concentrations without dephosphorylation in peripheral blood mononuclear cells by LC/MS/MS.
  Journal of pharmaceutical and biomedical analysis 2001 Chi J, Jayewardene A, Stone J, Gambertoglio JG, Aweeka FT
• An LC-MS-MS method for the determination of indinavir, an HIV-1 protease inhibitor, in human plasma.
  Journal of pharmaceutical and biomedical analysis 2001 Jayewardene AL, Kearney B, Stone JA, Gambertoglio JG, Aweeka FT
• Making the most of sparse clinical data by using a predictive-model-based analysis, illustrated with a stavudine pharmacokinetic study.
  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2001 Zhang L, Price R, Aweeka F, Bellibas SE, Sheiner LB
• Drug concentration monitoring of immunosuppressive agents: focus on tacrolimus, mycophenolate mofetil and sirolimus.
  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2000 Tsunoda SM, Aweeka FT
• Liquid chromatographic determination of urinary 6beta-hydroxycortisol to assess cytochrome p-450 3A activity in HIV positive pregnant women.
  Journal of pharmaceutical and biomedical analysis 2000 Homma M, Beckerman K, Hayashi S, Jayewardene AL, Oka K, Gambertoglio JG, Aweeka FT
• Pharmacokinetics of indinavir in HIV-positive pregnant women.
  AIDS (London, England) 2000 Hayashi S, Beckerman K, Homma M, Kosel BW, Aweeka FT
• Drug interactions of antiretroviral agents.
  AIDS clinical review 2000 Kosel BW, Aweeka F
• The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
  British journal of clinical pharmacology 2000 Aweeka F, Jayesekara D, Horton M, Swan S, Lambrecht L, Wilner KD, Sherwood J, Anziano RJ, Smolarek TA, Turncliff RZ
• High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes.
  Antimicrobial agents and chemotherapy 1999 Homma M, Jayewardene AL, Gambertoglio J, Aweeka F
• The penetration of anti-infectives into the central nervous system.
  Neurologic clinics 1999 Kearney BP, Aweeka FT
• Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients.
  Journal of clinical pharmacology 1999 Hayashi S, Jayesekera D, Jayewardene A, Shah A, Thevanayagam L, Aweeka F
• Antiviral therapy for HIV patients with renal insufficiency.
  Journal of acquired immune deficiency syndromes (1999) 1999 Jayasekara D, Aweeka FT, Rodriguez R, Kalayjian RC, Humphreys MH, Gambertoglio JG
• Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.
  AIDS (London, England) 1999 Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, Aweeka F, Deeks S, Price RW
• Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease.
  Epilepsia 1999 Aweeka FT, Gottwald MD, Gambertoglio JG, Wright TL, Boyer TD, Pollock AS, Eldon MA, Kugler AR, Alldredge BK
• Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations.
  Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1999 Aweeka FT, Jacobson MA, Martin-Munley S, Hedman A, Schoenfeld P, Omachi R, Tsunoda S, Gambertoglio JG
• Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex.
  Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1999 Aweeka F, Jayewardene A, Staprans S, Bellibas SE, Kearney B, Lizak P, Novakovic-Agopian T, Price RW
• Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
  Clinical pharmacology and therapeutics 1999 Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT
• Simple high-performance liquid chromatographic determination of the protease inhibitor indinavir in human plasma.
  Journal of chromatography. B, Biomedical sciences and applications 1998 Jayewardene AL, Zhu F, Aweeka FT, Gambertoglio JG
• Is there a pharmacokinetic interaction between foscarnet and zalcitabine during concomitant administration?
  Clinical therapeutics 1998 Aweeka FT, Brody SR, Jacobson M, Botwin K, Martin-Munley S
• Pharmacokinetics of intracellular zidovudine and its phosphorylated anabolites in the absence and presence of stavudine using an in vitro human peripheral blood mononuclear cell (PBMC) model.
  International journal of antimicrobial agents 1997 Brody SR, Aweeka FT
• Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients.
  Pharmacotherapy 1997 Wolfe EJ, Mathur V, Tomlanovich S, Jung D, Wong R, Griffy K, Aweeka FT
• Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor: the effects of zidovudine.
  Journal of clinical pharmacology 1996 Aweeka FT, Kwong M, Mak M, al-Uzri A, Affrime M, Cutler D, Kahn J, Gambertoglio JG
• Disposition of foscarnet during peritoneal dialysis.
  The Annals of pharmacotherapy 1996 Alexander AC, Akers A, Matzke GR, Aweeka FT, Fraley DS
• Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients.
  AIDS (London, England) 1996 Drusano GL, Aweeka F, Gambertoglio J, Jacobson M, Polis M, Lane HC, Eaton C, Martin-Munley S
• The use of therapeutic drug monitoring to optimise immunosuppressive therapy.
  Clinical pharmacokinetics 1996 Tsunoda SM, Aweeka FT
• Immunopharmacodynamic studies of cyclosporine in patients awaiting renal transplantation.
  Journal of clinical pharmacology 1995 d'Uscio CH, Aweeka FT, Prueksaritanont T, Tomlanovich SJ, Gupta SK, Lantz MV, Gambertoglio JG, Garovoy MR, Benet LZ
• Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor.
  Journal of clinical pharmacology 1995 Aweeka FT, Mak M, al-Uzri A, Peter K, Dett C, Franco J, Affrime M, Guerciolini R, Cutler DL, Kahn J
• Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.
  Clinical pharmacology and therapeutics 1995 Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, Jacobson MA
• Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
  Journal of clinical pharmacology 1994 Aweeka FT, Tomlanovich SJ, Prueksaritanont T, Gupta SK, Benet LZ
• Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).
  Antimicrobial agents and chemotherapy 1992 Aweeka FT, Gambertoglio JG, van der Horst C, Raasch R, Jacobson MA
• Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism.
  The Journal of clinical endocrinology and metabolism 1991 Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA
• Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection.
  Journal of chromatography 1990 Hassanzadeh MK, Aweeka FT, Wu S, Jacobson MA, Gambertoglio JG
• Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
  Antimicrobial agents and chemotherapy 1989 Aweeka F, Gambertoglio J, Mills J, Jacobson MA
• Interleukin-2 and immunoglobulin increases with H2-antagonists in humans.
  Transplantation proceedings 1989 Aweeka F, Lizak P, Garovoy M, Amend W, Birnbaum J, Gumbert M, Gambertoglio J
• Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
  The Journal of infectious diseases 1988 Jacobson MA, Crowe S, Levy J, Aweeka F, Gambertoglio J, McManus N, Mills J